Dulaglutide (DULA)

Dulaglutide (Trulicity) is a long-acting GLP-1 receptor agonist developed by Eli Lilly, approved by the FDA in 2014 for type 2 diabetes. The molecule is a fusion protein consisting of two copies of a modified GLP-1(7-37) analog linked to a modified human IgG4 Fc fragment via a small peptide linker. The REWIND cardiovascular outcomes trial was landmark — it was the first GLP-1 agonist trial to show cardiovascular benefit in a population where most participants did not have established cardiovascular disease.

Key Data

Research Status

FDA Approved

Half-Life

~5 days

Administration

Subcutaneous injection

Typical Dosage

0.75-4.5 mg once weekly

Molecular Weight

~63,000 Da (fusion protein)

Mechanism of Action

Dulaglutide activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite. The Fc fragment provides extended half-life through FcRn-mediated recycling and reduced renal clearance.

Reported Benefits

• FDA-approved for type 2 diabetes
• Once-weekly dosing convenience
• Cardiovascular risk reduction (REWIND)
• HbA1c reduction
• Body weight reduction
• Pre-filled pen (no mixing required)

All information is presented for Research Use Only (RUO). Not medical advice.